Innovent Biologics, Inc. (HKG: 1801), based in China, has announced the initiation of its Phase I clinical study for IBI3002, a pioneering bispecific antibody designed to target Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). This innovative therapy aims to address asthma and other type 2 inflammatory diseases and has commenced dosing in Australia.
The study is a randomized, double-blind, placebo-controlled trial featuring a single ascending dose design. It will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)—the latter specifically in participants with asthma—among healthy individuals and those with mild to moderate asthma. The findings will inform the global clinical development strategy for IBI3002.- Flcube.com
